Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response

Blood. 2011 Nov 10;118(19):5096-8. doi: 10.1182/blood-2011-03-335588. Epub 2011 Aug 29.

Authors

Lydia Roy¹, Cécile Tomowiak, François Guilhot

Affiliation

¹ Department of Onco-Hematology, Centre Hospitalier Universitaire de Poitiers, France.

PMID: 21876122
DOI: 10.1182/blood-2011-03-335588

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use
Benzamides
Dasatinib
Humans
Hydroxyurea / therapeutic use
Imatinib Mesylate
Leukemia, Myeloid, Chronic-Phase / blood
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Leukemia, Myeloid, Chronic-Phase / genetics
Male
Middle Aged
Piperazines / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / therapeutic use
Risk Factors
Thiazoles / therapeutic use

Substances

Antineoplastic Agents
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Thiazoles
Imatinib Mesylate
Protein-Tyrosine Kinases
nilotinib
Dasatinib
Hydroxyurea